1. Aitken M, Kleinrock M, Simorellis A, Nass D (2018) Global oncology trends 2018. Innovation, expansion and disruption. IQVIA Institute for Human Data Science, Parsippany
2. Cole A, Lundquist A, Lorgelly P, Norrlid H, Schaffer SK, Lewis F et al (2016) Improving efficiency and resource allocation in future cancer care. The Swedish Institute for Health Economics, Lund
3. Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A (2017) Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by the European Medicines Agency: retrospective cohort study of drug approvals 2009–13. BMJ 359:j4530.
https://doi.org/10.1136/bmj.j4530
4. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW (2015) Methods for the economic evaluation of health care programmes, 4. Aufl. Oxford University Press, Oxford
5. Garattini S (2016) The European Medicines Agency is still too close to industry. BMJ 353:i2412.
https://doi.org/10.1136/bmj.i2412